Overview

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

Status:
Recruiting
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind and parallel group study to compare the pharmacokinetic and safety of QL1203 and Vectibix® in healthy males.
Phase:
Phase 1
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Panitumumab